TechVision Expert Circle
Nov 2, 2026 · Industry Insights
Retatrutide TRIUMPH-3: 28% Weight Loss & Sleep Apnea Remission in Phase 3
Eli Lilly's phase 3 TRIUMPH-3 trial shows retatrutide, a triple GLP-1/GIP/GCGR agonist, achieves 28.1% average weight loss and reduces apnea-hypopnea index by 29.3 events/hour, with 52% of patients reaching OSA remission, outperforming semaglutide and tirzepatide.
Eli LillyGCGRGIP
0 likes · 14 min read